Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Michael Lincoff

Showing results (221-230 of 353) with videos related to

Pageof 36
Sort By:
JACC. Cardiovascular Interventions|February 26, 2011
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary interventionFreek W A Verheugt, Steven R Steinhubl, Martial Hamon, et al.
European Heart Journal|April 1, 2005
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trialBrahmajee K Nallamothu, Eric R Bates, Judith S Hochman, et al.
JAMA Internal Medicine|February 5, 2024
Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical TrialShalender Bhasin, A Michael Lincoff, Steven E Nissen, et al.
American Heart Journal|April 4, 2025
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)Leslie Cho, Stephen J Nicholls, Børge G Nordestgaard, et al.
The American Journal of Cardiology|January 18, 2026
Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI Patients With Non-System DelaySachin Kumar, Abhishek R Giri, Raunak M Nair, et al.
Journal of the American College of Cardiology|May 3, 2008
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trialHarvey D White, Derek P Chew, James W Hoekstra, et al.
The American Journal of Medicine|March 28, 2017
Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary SyndromeNuccia Morici, Stefano Savonitto, Claudio Ponticelli, et al.
BMJ Open Diabetes Research & Care|March 18, 2020
Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trialVenu Menon, Anirudh Kumar, Divyang R Patel, et al.
Circulation. Genomic and Precision Medicine|January 4, 2020
Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control StudyConnor A Emdin, Pallav Bhatnagar, Minxian Wang, et al.
JAMA|April 2, 2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialSteven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Pageof 36

Showing results (221-230 of 353) with videos related to

Sort By:
Pageof 36
JACC. Cardiovascular Interventions|February 26, 2011
Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary interventionFreek W A Verheugt, Steven R Steinhubl, Martial Hamon, et al.
European Heart Journal|April 1, 2005
Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trialBrahmajee K Nallamothu, Eric R Bates, Judith S Hochman, et al.
JAMA Internal Medicine|February 5, 2024
Effect of Testosterone on Progression From Prediabetes to Diabetes in Men With Hypogonadism: A Substudy of the TRAVERSE Randomized Clinical TrialShalender Bhasin, A Michael Lincoff, Steven E Nissen, et al.
American Heart Journal|April 4, 2025
Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a)Leslie Cho, Stephen J Nicholls, Børge G Nordestgaard, et al.
The American Journal of Cardiology|January 18, 2026
Impact Of Comprehensive STEMI Protocol On Process Metrics And Clinical Outcomes In STEMI Patients With Non-System DelaySachin Kumar, Abhishek R Giri, Raunak M Nair, et al.
Journal of the American College of Cardiology|May 3, 2008
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trialHarvey D White, Derek P Chew, James W Hoekstra, et al.
The American Journal of Medicine|March 28, 2017
Post-Discharge Worsening Renal Function in Patients with Type 2 Diabetes and Recent Acute Coronary SyndromeNuccia Morici, Stefano Savonitto, Claudio Ponticelli, et al.
BMJ Open Diabetes Research & Care|March 18, 2020
Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trialVenu Menon, Anirudh Kumar, Divyang R Patel, et al.
Circulation. Genomic and Precision Medicine|January 4, 2020
Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control StudyConnor A Emdin, Pallav Bhatnagar, Minxian Wang, et al.
JAMA|April 2, 2008
Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialSteven E Nissen, Stephen J Nicholls, Kathy Wolski, et al.
Pageof 36